Tag: NOVEL

  • TAK-653 (NBI-1065845)

    Non-desensitizing AMPA receptor positive allosteric modulator

    A low-impairment AMPA receptor potentiator advanced through Phase 2 in treatment-resistant depression by Takeda and Neurocrine, distinguished from earlier ampakines by minimal receptor desensitization.

    Abstract

    TAK-653 (also designated NBI-1065845; emraclidine has the same NBI prefix, distinct compound; CAS 1626387-80-1; molecular formula C19H21F3N4O3S; molecular weight 442.46) is a small-molecule non-desensitizing positive allosteric modulator of AMPA-class glutamate receptors developed by Takeda and out-licensed to Neurocrine Biosciences for clinical development in treatment-resistant depression. The compound was selected from a structural class designed to achieve allosteric AMPA potentiation without the receptor desensitization characteristic of earlier ampakines (CX-516, CX-546), which limited potency and produced cognitive impairment at higher doses. TAK-653 binds at an allosteric site distinct from the glutamate-binding domain, slowing AMPA receptor deactivation and increasing the integrated current produced by physiological glutamate transients without persistent receptor activation in the absence of glutamate; this profile produces synaptic potentiation under physiological signaling without the off-target excitotoxicity concerns of full agonists or strongly desensitizing modulators. Phase 1 imaging studies report dose-dependent BOLD signal modulation in cortical regions consistent with AMPA potentiation. The compound was advanced through Phase 2 in treatment-resistant depression by Neurocrine; published Phase 2a results from 2023 reported numerical separation from placebo on Hamilton Depression Rating Scale change at week 4 with improvement maintained through week 8, with a favorable safety profile (no seizures, no notable sedation, no dose-limiting cognitive impairment). The compound has not yet received regulatory approval as of the most recent monograph revision. Distinguishing features versus other AMPA modulators are the absence of receptor desensitization, the minimal impairment profile at antidepressant doses, and the rapid-onset depression treatment positioning targeting the same therapeutic niche as ketamine and esketamine.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Tropisetron

    Selective 5-HT3 receptor antagonist with alpha-7 nicotinic acetylcholine receptor partial agonism

    A serotonergic indolylcarboxylate ester developed at Sandoz as a chemotherapy-induced antiemetic, distinguished from other setrons by intrinsic partial agonist activity at the alpha-7 nicotinic acetylcholine receptor and downstream cognitive, anti-inflammatory, and analgesic activity.

    Abstract

    Tropisetron, the indol-3-carboxylate ester of tropine and the third selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist introduced for the management of chemotherapy-induced and postoperative nausea and vomiting, is a clinically marketed antiemetic in approximately 50 jurisdictions outside the United States and a research compound of escalating interest in cognition, central nervous system inflammation, fibromyalgia, and Alzheimer’s disease. Distinct from ondansetron and granisetron in pharmacology though not in marketed indication, tropisetron is a dual-mechanism agent: at the 5-HT3 ligand-gated cation channel it produces insurmountable, low-nanomolar antagonism with approximately 1000-fold selectivity over other monoamine receptors, while at the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor it acts as a potent partial agonist with low-micromolar functional activity in heterologous expression systems and in cortical and hippocampal neurons. The compound is well tolerated at registered doses; the principal short-term adverse events are dose-dependent constipation, headache, and transient hypertension, and rare clinically significant arrhythmia is captured in pooled postmarketing data and prescribing labels. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • GTS-21

    Alpha-7 nicotinic acetylcholine receptor partial agonist with alpha-4-beta-2 cross-reactivity, derivative of the natural marine alkaloid anabaseine

    A 3-(2,4-dimethoxybenzylidene)anabaseine derivative of the marine nemertine-worm alkaloid anabaseine, characterized in the laboratory of William Kem at the University of Florida and advanced through Phase 1 and Phase 2 clinical development for schizophrenia cognitive impairment, Alzheimer disease, and selected exploratory cognitive endpoints. The longest-studied alpha-7 nicotinic partial agonist in cognitive applications and the principal historical reference compound for the receptor class.

    Abstract

    GTS-21 (also known as DMXBA, DMBX-anabaseine, and 3-(2,4-dimethoxybenzylidene)anabaseine) is a small-molecule partial agonist of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor. The compound is a synthetic derivative of the natural product anabaseine, a marine alkaloid originally isolated from nemertine ribbonworms and from certain ant species, characterized chemically and pharmacologically by William Kem at the University of Florida beginning in the late 1970s. Anabaseine itself is a non-selective nicotinic receptor agonist with substantial muscle-type alpha-1 nicotinic activity that produces neuromuscular toxicity at doses producing central nervous system effects. The 3-(2,4-dimethoxybenzylidene) substitution at the anabaseine scaffold (the structural feature defining DMXBA) substantially increases alpha-7 nicotinic receptor selectivity over the muscle-type receptor and produces the partial agonist functional profile that has supported clinical development. Functional intrinsic activity at human alpha-7 nicotinic receptors expressed in heterologous systems is approximately 30 to 50 percent of the acetylcholine maximum response. Selectivity over the alpha-4-beta-2 nicotinic subtype is incomplete: GTS-21 binds alpha-4-beta-2 with affinity comparable to alpha-7 and acts as a partial agonist at alpha-4-beta-2 in some functional assays and as an antagonist in others, contributing complexity to the in vivo pharmacology that distinguishes GTS-21 from the more selective subsequent candidates encenicline, bradanicline, and PHA-543613. The compound is the longest-studied alpha-7 nicotinic partial agonist in cognitive applications, with continuous research from the early 1990s through the 2020s, and is the principal historical reference compound for the receptor class. GTS-21 was advanced through multiple Phase 1 studies in healthy volunteers in the 1990s and 2000s with positive cognitive signals (the original Kitagawa et al. 2003 healthy volunteer report demonstrated improvements on the Connors Continuous Performance Test), through several Phase 2 studies in schizophrenia cognitive impairment (Olincy et al. 2006 immediate-release proof-of-concept; Olincy et al. 2017 extended-release confirmatory), and through Phase 2 studies in Alzheimer disease and other exploratory cognitive indications. The clinical results have been consistent with a small effect size that produced significant signals in some early studies and not in subsequent larger studies. The compound is metabolized to two principal active metabolites (4-OH-GTS-21 and 2-OH-GTS-21) that retain alpha-7 nicotinic partial agonist activity and contribute to the pharmacodynamic profile; the metabolite contribution complicates the dose-response interpretation and was the principal motivation for the extended-release formulation tested in the Olincy 2017 study. The compound is not in active commercial development as of the most recent monograph revision; research-grade GTS-21 is widely available and continues to be used as a reference alpha-7 partial agonist in fundamental pharmacology. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • NACET

    Lipophilic ester of N-acetylcysteine and glutathione precursor

    The ethyl ester of N-acetylcysteine, a lipophilic NAC analog with substantially higher cellular and central nervous system bioavailability than the parent acid.

    Abstract

    NACET (N-acetyl-L-cysteine ethyl ester; CAS 59587-09-6; molecular formula C7H13NO3S; molecular weight 191.25) is the ethyl ester prodrug of N-acetylcysteine (NAC), developed at the University of Southern California and at Italian academic groups during the 2000s as a lipophilic alternative to NAC with markedly improved cellular and central nervous system bioavailability. The parent NAC is a polar carboxylic acid with low oral bioavailability (approximately 6 to 10 percent), poor blood-brain barrier penetration, and limited intracellular accumulation; NACET is a neutral ester at physiological pH, crosses cell membranes by passive diffusion, and is hydrolyzed intracellularly by ubiquitous esterases to release NAC inside the cell. Published in vitro studies report cellular glutathione (GSH) elevation 30 to 50 percent above baseline after NACET exposure compared to less than 10 percent for equimolar NAC, owing to the difference in cellular delivery. Published rodent in vivo work reports brain GSH elevation after oral NACET that is not detectable after equimolar oral NAC, consistent with the BBB-penetration argument. The pharmacological consequence is that NACET delivers the antioxidant and glutathione-precursor activity of NAC at lower oral doses with central nervous system exposure. Reported applications in research include neuroprotection, oxidative stress modulation, and as a research tool for cysteine delivery in cell culture. Human pharmacokinetic data are limited and no large clinical trials have been published. The compound is not approved by FDA or EMA for any indication. NAC itself is approved as an antidote for acetaminophen overdose and as a mucolytic; the ester form is sold only as a research-grade compound or supplement. Stability is moderate at room temperature; refrigerated storage is preferred for solid material.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Encenicline

    Selective alpha-7 nicotinic acetylcholine receptor partial agonist

    A quinuclidine benzothiophene-2-carboxamide developed at EnVivo and advanced by Forum Pharmaceuticals through two global Phase 3 programs in schizophrenia cognitive impairment and one Phase 3 program in Alzheimer disease, terminated in March 2016 after both Phase 3 schizophrenia trials missed co-primary endpoints and following a September 2015 FDA clinical hold for severe gastrointestinal adverse events.

    Abstract

    Encenicline (development codes EVP-6124 and MT-4666) is a small-molecule selective partial agonist of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor (alpha-7 nAChR), distinguished from earlier candidates in the class by its high subtype selectivity, the relatively favorable functional intrinsic activity profile (60 to 70 percent of the acetylcholine maximum response in heterologous expression systems), and a clinical development trajectory that reached two global Phase 3 programs in cognitive impairment associated with schizophrenia (CIAS-1 and CIAS-2) and one Phase 3 program in Alzheimer disease (COGNITIV-AD). The compound was originated at EnVivo Pharmaceuticals (later renamed Forum Pharmaceuticals) following the 2008 acquisition of the parent quinuclidine benzothiophene chemistry program from Bayer, and was advanced through Phase 1 first-in-human studies in 2010 to 2012, through positive Phase 2 schizophrenia and Alzheimer disease readouts in 2013 to 2015 with effect sizes of approximately Cohen’s d 0.3 to 0.5 on cognitive composite measures, and into the Phase 3 program from 2014. In September 2015 the United States Food and Drug Administration placed the Phase 3 schizophrenia trials and the Alzheimer disease trial on partial clinical hold following reports of severe gastrointestinal adverse events including nausea, vomiting, and gastrointestinal ulceration in a small fraction of patients; the hold was partially lifted in November 2015 to permit completion of the schizophrenia Phase 3 studies under modified safety protocols. In March 2016 Forum announced that both Phase 3 schizophrenia trials had missed their co-primary cognitive and functional endpoints and the program was discontinued. Forum Pharmaceuticals was wound down in 2016. Encenicline represents the most clinically developed alpha-7 nicotinic partial agonist in cognitive applications and is the principal source of the contemporary scientific assessment that monoselective alpha-7 partial agonism, despite robust preclinical pharmacology and Phase 2 cognitive signals, has not produced clinically meaningful improvement at the registration threshold in the indications studied. The compound remains commercially unavailable but is supplied as a research-grade reagent (greater than 98 percent purity) by multiple chemical suppliers and continues to serve as a reference alpha-7 nicotinic partial agonist for fundamental pharmacology research and for combination-pharmacology investigations. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Testagen

    Synthetic tetrapeptide bioregulator with testicular tissue-specific epigenetic and steroidogenesis-modulating activity

    A synthetic tetrapeptide (Lys-Glu-Asp-Gly) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as the defined active sequence of the testicular polypeptide complex Testoluten, proposed to modulate steroidogenic gene expression and Leydig cell function through direct peptide-DNA interaction and chromatin remodeling in testicular endocrine tissue.

    Abstract

    Testagen, the synthetic tetrapeptide Lys-Glu-Asp-Gly (one-letter code KEDG; molecular formula C17H29N5O9; molecular weight 447.44), is a testicular-derived bioregulatory peptide synthesized and characterized by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology (IBG) beginning in the early 2000s. The compound belongs to the Khavinson class of ultrashort (two to seven residue) peptide bioregulators, a family of synthetic sequences modeled on tissue-specific peptide fragments isolated from organ extracts by acid-pepsin hydrolysis and ultrafiltration, and is the defined synthetic analog of the active component of the testicular polypeptide complex preparation Testoluten [1, 2]. Testagen is distinguished within the Khavinson bioregulator family by a testicular tissue-directed pharmacological profile that centers on three proposed activities: first, modulation of steroidogenic gene expression in Leydig cells, with reported effects on expression of genes encoding steroidogenic acute regulatory protein (StAR), cholesterol side-chain cleavage enzyme (CYP11A1), 3-beta-hydroxysteroid dehydrogenase (3-beta-HSD), and 17-beta-hydroxysteroid dehydrogenase, the principal rate-limiting enzymes in the testosterone biosynthetic cascade from cholesterol to testosterone [3, 4]; second, epigenetic modulation through direct peptide-DNA interaction and chromatin remodeling, consistent with the broader Khavinson hypothesis that ultrashort peptides act as sequence-specific regulators of gene expression through complementary electrostatic interactions with DNA in gene promoter regions [5, 6]; and third, normalization of hypothalamic-pituitary-gonadal (HPG) axis signaling in aged animal models, with reported restoration of luteinizing hormone receptor expression on Leydig cells and normalization of the testosterone-to-luteinizing hormone ratio [7, 8]. The compound shares the general Khavinson bioregulator mechanism of cell and nuclear membrane penetration, direct interaction with histone proteins and double-stranded DNA, and modulation of gene transcription, a framework supported by fluorescence microscopy tracking of labeled peptide analogs into cell nuclei and by electrophoretic mobility shift assays demonstrating peptide-DNA complex formation [5, 6]. Structurally, Testagen differs from the closely related Khavinson bioregulators Epithalon (Ala-Glu-Asp-Gly, pineal-derived), Livagen (Lys-Glu-Asp-Ala, liver-derived), and Cortagen (Ala-Glu-Asp-Pro, brain-derived) by single residue substitutions that are proposed to confer tissue-specificity through differential DNA sequence recognition [9]. The substitution of lysine at position 1 (versus alanine in Epithalon) and glycine at position 4 (versus alanine in Livagen) produces a distinct charge distribution and hydrogen-bonding pattern that molecular modeling studies have associated with preferential interaction with promoter sequences of testicular steroidogenic genes [5, 10]. No formal pharmacokinetic studies have been published for Testagen. The compound, as a linear tetrapeptide with unprotected termini, is expected to undergo rapid proteolytic degradation by aminopeptidases and carboxypeptidases in plasma and gastrointestinal fluid, with a predicted plasma half-life on the order of minutes. No human clinical trials of the synthetic KEDG tetrapeptide have been registered on ClinicalTrials.gov or on major international trial registries. The clinical evidence base is limited to a single uncontrolled Russian-language clinical study and to ex vivo human cell studies. The parent polypeptide complex Testoluten has been used in Russian gerontological clinical practice for age-related testosterone decline and male subfertility, but the synthetic tetrapeptide does not hold separate pharmaceutical registration in any jurisdiction. Testagen is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. It is supplied as a research-grade lyophilized powder by multiple peptide suppliers at greater than 95 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • N-PEP-12

    Cerebrolysin-derived oral peptide fraction

    A defined oral peptide fraction prepared from porcine brain tissue, marketed as a nutraceutical analog of intravenous Cerebrolysin for cognitive support.

    Abstract

    N-PEP-12 is a porcine-brain-derived peptide preparation developed by Ever Neuro Pharma (the manufacturer of Cerebrolysin) as a defined orally bioavailable analog of the parent intravenous nootropic. Cerebrolysin itself is a complex hydrolysate of porcine cerebral cortex containing approximately 25 percent free amino acids and 75 percent low-molecular-weight peptides (less than 10 kDa) administered by daily intravenous or intramuscular injection in courses of 10 to 30 days for vascular dementia, Alzheimer’s disease, ischemic stroke recovery, and traumatic brain injury indications across approximately 50 jurisdictions (Europe, Asia, Russia, South America). The intravenous administration is operationally restrictive; N-PEP-12 was developed to provide a similar peptide profile in a daily oral capsule format suitable for outpatient and over-the-counter use. The published characterization describes a peptide molecular weight distribution of 1 to 10 kDa with similar amino acid composition to Cerebrolysin and shared neurotrophic activity in cortical neuron culture (BDNF and IGF-1 mimetic effects, neurite outgrowth, protection against amyloid-beta and glutamate excitotoxicity). Clinical evidence is more limited than for Cerebrolysin: published randomized trials in mild cognitive impairment (MCI) and age-associated memory impairment report modest cognitive improvements over 90 days in single-center studies. The compound is not FDA-approved; it is marketed as a dietary supplement in the United States and as a nutraceutical or medicinal food in European jurisdictions. The principal limitation on the strength of the evidence is the small number of independent clinical trials and the dominance of the manufacturer-sponsored published record.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Bradanicline

    Selective alpha-7 nicotinic acetylcholine receptor full agonist

    A quinuclidine benzofuran-2-carboxamide developed at Targacept as a selective alpha-7 nicotinic full agonist with a binding affinity of 1.4 nanomolar at the human alpha-7 receptor, advanced through Phase 2 development for cognitive impairment and negative symptoms of schizophrenia with a positive 12-week exploratory trial followed by a negative larger 24-week confirmatory trial, subsequently licensed to Anvylic Therapeutics for Tourette syndrome and other indications.

    Abstract

    Bradanicline (development codes TC-5619 and ATA-101) is a small-molecule, highly selective full agonist of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor (alpha-7 nAChR), originated at Targacept Pharmaceuticals (Winston-Salem, North Carolina) from a quinuclidine benzofuran-2-carboxamide chemistry program in the mid-2000s and advanced through Phase 1 and Phase 2 clinical development for cognitive impairment associated with schizophrenia. The compound binds the human alpha-7 nicotinic receptor with a Ki of approximately 1.4 nanomolar, slightly higher affinity than encenicline (Ki approximately 4 nanomolar) and substantially higher affinity than tropisetron at the alpha-7 site, and exhibits functional intrinsic activity of approximately 80 to 90 percent of the acetylcholine maximum response in heterologous expression systems, placing it in the high-efficacy stratum of alpha-7 ligands as a full agonist rather than the partial-agonist class that encenicline and tropisetron occupy. The full-agonist intrinsic activity is the principal medicinal-chemistry differentiator of bradanicline within the broader quinuclidine-amide chemical class. Selectivity over alpha-4-beta-2, alpha-3-beta-4, alpha-3-beta-2, and other neuronal nicotinic subtypes is approximately 100-fold or greater. Targacept terminated the cognitive impairment program in 2013 and the compound was subsequently licensed to Catalyst Biosciences and to Anvylic Therapeutics for Tourette syndrome and selected other neurological indications. The compound represents a useful research-clinical reference for the alpha-7 nicotinic full-agonist class and for the assessment of whether higher functional intrinsic activity at the receptor produces greater clinical benefit. Bradanicline did not produce the severe gastrointestinal toxicity that triggered the September 2015 FDA clinical hold on encenicline; the safety profile in Phase 2 was well-tolerated with no clinically noteworthy findings reported. The compound is supplied as a research-grade reagent (greater than 98 percent purity) by multiple chemical suppliers and continues to serve as a reference alpha-7 nicotinic full agonist for fundamental pharmacology research. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • FGL Peptide

    NCAM-derived FGFR-agonist peptide

    A 15-residue synthetic peptide modeled on the second fibronectin-like domain of neural cell adhesion molecule, an FGFR1 partial agonist with neuroprotective and pro-cognitive activity in rodent models.

    Abstract

    FGL (FG Loop peptide; Glu-Val-Tyr-Val-Val-Ala-Glu-Asn-Gln-Gln-Gly-Lys-Ser-Lys-Ala; sometimes called the FGL peptide or NCAM-derived FGFR agonist; molecular weight approximately 1622 Da) is a synthetic 15-residue peptide modeled on the second fibronectin type III repeat (FnIII) domain of neural cell adhesion molecule (NCAM), specifically the Phe-Gly loop responsible for fibroblast growth factor receptor 1 (FGFR1) interaction. NCAM is a transmembrane glycoprotein expressed at high levels in developing and adult nervous system tissue that mediates cell-cell adhesion through homophilic NCAM-NCAM binding and signals across the membrane through cis-binding to FGFR1. The FGL peptide was designed at the University of Copenhagen by Elisabeth Bock and Vladimir Berezin as a small-molecule mimetic of the NCAM-FGFR interaction, capable of activating FGFR1 signaling without the broad effects of full NCAM ectodomain or full-length FGF ligands. Reported activities include neurite outgrowth promotion in primary cortical and hippocampal neurons, protection against glutamate excitotoxicity, anxiolysis and pro-cognitive effects in rodent fear conditioning and Morris water maze paradigms, and recovery promotion in models of traumatic brain injury and stroke. Routes studied include subcutaneous, intraperitoneal, and intranasal administration. Plasma half-life is short (approximately 30 minutes); the central nervous system exposure after intranasal administration is substantially higher than after parenteral routes, owing to direct olfactory and trigeminal pathway transport. The compound advanced through ENKAM Pharmaceuticals (a University of Copenhagen spin-out) into early clinical development for Alzheimer’s disease and cognitive impairment in the late 2000s; clinical development has not produced a marketed agent. The principal limitation on the strength of the evidence is the dominance of the originating laboratory’s publications and the absence of independent replication of key behavioral findings.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • AVL-3288

    Type I positive allosteric modulator of the alpha-7 nicotinic acetylcholine receptor

    An isoxazole-acrylamide chemical entity originally developed at the University of California Irvine as compound CCMI and licensed through multiple owners to Anvylic Therapeutics, representing the most mechanistically distinct alpha-7 nicotinic candidate in clinical development through its Type I positive allosteric modulator mechanism that preserves the spatiotemporal specificity of endogenous cholinergic neurotransmission.

    Abstract

    AVL-3288 (also known as UCI-4083, CCMI, Anvylic-3288, and XY-4083) is a small-molecule, orally bioavailable Type I positive allosteric modulator (PAM) of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor (alpha-7 nAChR). The compound is mechanistically distinct from the partial-agonist (tropisetron, encenicline, GTS-21) and full-agonist (bradanicline, PHA-543613) classes that have dominated alpha-7 nicotinic receptor drug development. Type I PAMs bind the alpha-7 receptor at an allosteric site distinct from the orthosteric (acetylcholine) binding site, do not directly activate the receptor in the absence of agonist, and enhance the potency and efficacy of endogenous acetylcholine signaling at the receptor. Critically, Type I PAMs preserve the rapid desensitization kinetics of the alpha-7 channel and therefore preserve the spatiotemporal specificity of cholinergic neurotransmission, in contrast to direct agonists which prolong receptor activation and may produce non-physiological signaling. This mechanistic profile is the principal scientific argument for the AVL-3288 approach as an alternative to direct agonist development in cognitive applications, particularly in light of the September 2015 FDA clinical hold and March 2016 Phase 3 termination of encenicline (a partial agonist) for severe gastrointestinal toxicity. The compound has not advanced to Phase 2 as of the most recent monograph revision; future development depends on commercial-funding decisions. AVL-3288 represents the most mechanistically novel of the alpha-7 nicotinic receptor candidates and is the principal contemporary alternative therapeutic concept for the alpha-7 nicotinic target. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.